Appropriate Governance of the Life Sciences - 5 Health Innovation for the world ’ s poor : Who are the players and what is the game ?

Fundamental change seems increasingly inevitable, but at the same time increasingly unimaginable. A variety of public private partnering arrangements and innovative financing mechanisms has begun to change the neglected disease landscape over the last decade. How significant are these public-private partnership (PPP) arrangements? Are these players likely to endure? Do they deserve the continued support of development donors? How do they relate to broader shifts in the pharmaceutical sector landscape and the changing ‘rules of the game’?